跳至主要内容
临床试验/NCT03287843
NCT03287843已完成不适用

Effect of Timing of Surgery After Neoadjuvant Chemoradiation on Histopathological Results, Complications, Recurrence and Survivals for Locally Advanced Rectal Cancer

Ege University0 个研究点目标入组 350 人开始时间: 2006年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
350
主要终点
Pathological Complete Response Rate

研究概览

简要总结

This study aimed to compare the outcomes of early versus late surgical resection in patients who underwent curative total mesorectal excision after neoadjuvant chemoradiation. Half of the participants will undergo surgery before 8 weeks, while the other half will undergo surgery after 8 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinic stage II-III cancer ( T3- T4 tm or/and N(+) disease )
  • Patients with histologically confirmed adenocarcinoma of the rectum
  • Tumor distal border located within 15 cm. from anal verge (as measured by rigid rectoscopy)
  • Standardized total mesorectal excision surgery
  • Tumor must be clinically resectable with curative intent (R0 resection must be most likely)
  • Elective operation
  • The patient must consent to be in the study and the informed consent must be signed

排除标准

  • Clinic stage I and IV cancer disease
  • Patients with malignant disease of the rectum other than adenocarcinoma
  • Recurrent rectal cancer
  • Emergency cases (Mechanical bowel obstruction, perforation)
  • Other previous or concurrent malignancies
  • Any contraindication for radiochemotherapy
  • Previous chemotherapy or radiotherapy to the pelvis
  • Tumor has arisen from chronic inflammatory bowel disease or hereditary polyposis disease
  • American Society of Anesthesiologists Score >3 patients

结局指标

主要结局

Pathological Complete Response Rate

时间窗: 2 months

Complete pathological response, defined as the absence of viable tumor cells, may develop after neoadjuvant treatment for rectal cancer. Prognostic factors affecting pathological complete response will be evaluated.

次要结局

  • Disease-free Survival(5 years after surgery)
  • Tumour Regression Grade(30 days after surgery)
  • Surgical Complications(90 days after surgery)
  • Overall Survival(5 years after surgery)
  • Completeness of the Mesorectal Dissection(30 days after surgery)
  • Recurrence(5 years after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zekeriya Erhan Akgün

Professor of surgery

Ege University

相似试验

Appropriate Timing of Surgery After Neoadjuvant... | 临床试验